ESSA Pharma Inc. (NASDAQ:EPIX) Holdings Lifted by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC grew its holdings in shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 37.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 345,902 shares of the company’s stock after buying an additional 93,830 shares during the period. Parkman Healthcare Partners LLC’s holdings in ESSA Pharma were worth $2,096,000 as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Jefferies Financial Group cut ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Piper Sandler cut shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $15.00 to $2.00 in a research note on Monday, November 4th. Finally, Oppenheimer cut shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th.

ESSA Pharma Stock Performance

Shares of EPIX stock opened at $1.75 on Wednesday. ESSA Pharma Inc. has a 1 year low of $1.40 and a 1 year high of $11.67. The business’s fifty day moving average is $3.97 and its 200-day moving average is $4.96. The stock has a market cap of $77.65 million, a PE ratio of -2.82 and a beta of 1.62.

Insider Buying and Selling

In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $1.53, for a total value of $12,055,761.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 7,880,971 shares of company stock valued at $12,064,111 over the last three months. Company insiders own 14.70% of the company’s stock.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.